[go: up one dir, main page]

DK2358717T3 - Aminotetrahydropyraner som dipeptidylpeptidase-iv-inhibitorer tilbehandling eller forebyggelse af diabetes - Google Patents

Aminotetrahydropyraner som dipeptidylpeptidase-iv-inhibitorer tilbehandling eller forebyggelse af diabetes

Info

Publication number
DK2358717T3
DK2358717T3 DK09756204T DK09756204T DK2358717T3 DK 2358717 T3 DK2358717 T3 DK 2358717T3 DK 09756204 T DK09756204 T DK 09756204T DK 09756204 T DK09756204 T DK 09756204T DK 2358717 T3 DK2358717 T3 DK 2358717T3
Authority
DK
Denmark
Prior art keywords
diabetes
prevention
aminotetrahydropyranes
dipeptidylpeptidase
treatment
Prior art date
Application number
DK09756204T
Other languages
English (en)
Inventor
Tesfaye Biftu
Ping Chen
Jason M Cox
Ann E Weber
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41559521&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2358717(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of DK2358717T3 publication Critical patent/DK2358717T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK09756204T 2008-11-13 2009-11-11 Aminotetrahydropyraner som dipeptidylpeptidase-iv-inhibitorer tilbehandling eller forebyggelse af diabetes DK2358717T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19917908P 2008-11-13 2008-11-13
PCT/US2009/063976 WO2010056708A1 (en) 2008-11-13 2009-11-11 Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes

Publications (1)

Publication Number Publication Date
DK2358717T3 true DK2358717T3 (da) 2013-11-18

Family

ID=41559521

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09756204T DK2358717T3 (da) 2008-11-13 2009-11-11 Aminotetrahydropyraner som dipeptidylpeptidase-iv-inhibitorer tilbehandling eller forebyggelse af diabetes

Country Status (40)

Country Link
US (8) US8143289B2 (da)
EP (4) EP2358717B1 (da)
JP (2) JP4854825B1 (da)
KR (2) KR101454093B1 (da)
CN (1) CN102272136B (da)
AR (1) AR074306A1 (da)
AU (1) AU2009314191B2 (da)
BR (1) BRPI0921375B8 (da)
CA (1) CA2742783C (da)
CL (1) CL2011001082A1 (da)
CO (1) CO6382129A2 (da)
CR (1) CR20110257A (da)
CY (1) CY1114617T1 (da)
DK (1) DK2358717T3 (da)
DO (1) DOP2011000128A (da)
EA (1) EA018613B1 (da)
EC (1) ECSP11011044A (da)
ES (1) ES2432191T3 (da)
GE (1) GEP20135724B (da)
HK (1) HK1154849A1 (da)
HN (1) HN2011001256A (da)
HR (1) HRP20130924T1 (da)
IL (2) IL212485A (da)
JO (1) JO2870B1 (da)
MA (1) MA32887B1 (da)
MX (1) MX2011005044A (da)
MY (1) MY150787A (da)
NI (1) NI201100081A (da)
NZ (1) NZ592826A (da)
PA (1) PA8848201A1 (da)
PE (1) PE20120027A1 (da)
PL (1) PL2358717T3 (da)
PT (1) PT2358717E (da)
RS (1) RS52946B (da)
SI (1) SI2358717T1 (da)
SV (1) SV2011003903A (da)
TN (1) TN2011000201A1 (da)
TW (1) TWI398443B (da)
UA (1) UA101414C2 (da)
WO (1) WO2010056708A1 (da)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8841287B2 (en) 2008-06-12 2014-09-23 Janssen Pharmaceutica N.V. Diamino-pyridine, pyrimidine, and pyrazine modulators of the histamine H4 receptor
JO2870B1 (en) 2008-11-13 2015-03-15 ميرك شارب اند دوهم كورب Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes
JP5734981B2 (ja) * 2009-09-02 2015-06-17 メルク・シャープ・エンド・ドーム・コーポレイション 糖尿病の治療又は予防のためのジペプチジルペプチダーゼｉｖ阻害剤としてのアミノテトラヒドロピラン
US8716482B2 (en) 2009-09-25 2014-05-06 Merck Sharp & Dohme Corp. Substituted aminopiperidines as dipeptidyl peptidase-IV inhibitors for the treatment of diabetes
EP2538783B1 (en) 2010-02-22 2016-06-01 Merck Sharp & Dohme Corp. Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
EP2571876B1 (en) 2010-05-21 2016-09-07 Merck Sharp & Dohme Corp. Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
EP2648517B1 (en) 2010-12-06 2015-08-05 Merck Sharp & Dohme Corp. Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors
EP2714069A4 (en) * 2011-05-25 2015-06-24 Amylin Pharmaceuticals Llc LONG-TERM CONJUGATES WITH TWO HORMONES
KR20140034861A (ko) * 2011-06-29 2014-03-20 머크 샤프 앤드 돔 코포레이션 디펩티딜 펩티다제-iv 억제제의 신규한 결정질 형태
EP2729468A4 (en) 2011-07-05 2015-03-18 Merck Sharp & Dohme Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors
US9073930B2 (en) 2012-02-17 2015-07-07 Merck Sharp & Dohme Dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
US9315508B2 (en) 2012-07-23 2016-04-19 Merck Sharp & Dohme Corp. Treating diabetes with dipeptidyl peptidase-IV inhibitors
EP2874626A4 (en) 2012-07-23 2016-03-23 Merck Sharp & Dohme TREATMENT OF DIABETES WITH DIPEPTIDYLPEPTIDASE IV INHIBITORS
TWI500613B (zh) * 2012-10-17 2015-09-21 Cadila Healthcare Ltd 新穎之雜環化合物
US9937153B2 (en) 2013-08-30 2018-04-10 Merck Sharp & Dohme Ltd. Oral pharmaceutical formulation of omarigliptin
EP2997008B1 (en) * 2014-03-20 2016-06-29 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Process for the preparation of key intermediates of omarigliptin
CN105037367A (zh) * 2014-04-18 2015-11-11 四川海思科制药有限公司 氨基六元环类衍生物及其在医药上的应用
CN105085528A (zh) * 2014-05-15 2015-11-25 成都贝斯凯瑞生物科技有限公司 作为二肽基肽酶-iv抑制剂的氨基四氢吡喃衍生物
CN105085530B (zh) * 2014-05-23 2019-01-04 四川海思科制药有限公司 三元稠合环取代的氨基六元环类衍生物及其在医药上的应用
CN105518008B (zh) * 2014-06-17 2018-03-27 海思科医药集团股份有限公司 氨基吡喃环衍生物及其组合物和应用
CN105294694B (zh) * 2014-06-18 2019-01-04 四川海思科制药有限公司 氨基六元环类衍生物及其在医药上的应用
US9862725B2 (en) 2014-07-21 2018-01-09 Merck Sharp & Dohme Corp. Process for preparing chiral dipeptidyl peptidase-IV inhibitors
CN105985357A (zh) * 2015-02-12 2016-10-05 北京赛林泰医药技术有限公司 取代的氨基六元饱和杂脂环类长效dpp-iv抑制剂
CN107250135B (zh) * 2015-08-24 2020-05-26 四川科伦博泰生物医药股份有限公司 长效二肽基肽酶-ⅳ抑制剂、用途及其中间体的制备方法
CN106478631B (zh) * 2015-08-24 2019-04-05 四川科伦药物研究院有限公司 长效二肽基肽酶-iv抑制剂、用途及其中间体的制备方法
WO2017032705A1 (en) 2015-08-25 2017-03-02 Sandoz Ag Crystalline form of omarigliptin
TWI681962B (zh) * 2015-08-26 2020-01-11 大陸商四川海思科製藥有限公司 胺基六員環類衍生物及其在醫藥上的應用
TWI640524B (zh) * 2015-08-27 2018-11-11 四川海思科製藥有限公司 Aminopyran ring derivatives and compositions and uses thereof
CN105198847B (zh) * 2015-10-28 2017-05-17 四川凯科医药科技有限公司 一种化合物的制备方法
JP6475368B2 (ja) * 2015-12-03 2019-02-27 エッフェ・イ・エッセ − ファッブリカ・イタリアーナ・シンテテイチ・ソチエタ・ペル・アツィオーニＦ．Ｉ．Ｓ． − Ｆａｂｂｒｉｃａ Ｉｔａｌｉａｎａ Ｓｉｎｔｅｔｉｃｉ Ｓ．ｐ．Ａ． アミノテトラヒドロピラン類の製造方法
CN105399744B (zh) * 2015-12-17 2017-07-18 黄燕鸽 一种奥格列汀的合成方法
EP3181565A1 (en) 2015-12-18 2017-06-21 Sandoz Ag Crystalline omarigliptin salts
US10221185B2 (en) * 2015-12-25 2019-03-05 Sichuan Haisco Pharmaceutical Co., Ltd. Crystal form of substituted aminopyran derivativek
CN106916158A (zh) * 2015-12-25 2017-07-04 四川海思科制药有限公司 一种吡喃衍生物盐酸盐水合物及其中间体的制备方法
CN106928228B (zh) * 2015-12-29 2019-08-30 杭州普晒医药科技有限公司 奥格列汀盐及其晶型、它们的制备方法和药物组合物
CN107337674B (zh) * 2016-04-29 2019-09-20 江苏吉贝尔药业股份有限公司 用于dpp-iv抑制剂的四氢吡喃胺衍生物、其药物组合物和制剂以及用途
CN109071551B (zh) * 2016-05-25 2020-12-08 四川海思科制药有限公司 一种三氟甲基取代的吡喃衍生物的制备方法
WO2017202365A1 (zh) * 2016-05-25 2017-11-30 四川海思科制药有限公司 一种三氟甲基取代的吡喃衍生物制备方法
CN107652291B (zh) * 2016-07-26 2020-07-14 中国科学院上海药物研究所 一种制备手性四氢吡喃衍生物的方法
WO2018028666A1 (zh) * 2016-08-12 2018-02-15 正大天晴药业集团股份有限公司 Dpp-iv长效抑制剂的结晶及其盐
CN106674227B (zh) * 2016-12-06 2019-03-19 上海博志研新药物技术有限公司 一种奥格列汀及其中间体的制备方法
EP3335704A1 (en) 2016-12-16 2018-06-20 Hexal AG Pharmaceutical composition comprising omarigliptin
EP3335702A1 (en) 2016-12-16 2018-06-20 Hexal AG Pharmaceutical compositions comprising omarigliptin
EP3335701A1 (en) 2016-12-16 2018-06-20 Hexal AG Pharmaceutical composition comprising omarigliptin
EP3335703A1 (en) 2016-12-16 2018-06-20 Hexal AG Pharmaceutical composition comprising omarigliptin
CN107024590A (zh) * 2017-03-13 2017-08-08 新疆医科大学 一种诊断1型和2型糖尿病的血清蛋白标志物组
US11020412B2 (en) 2017-03-16 2021-06-01 Inventia Healthcare Limited Pharmaceutical composition comprising dapagliflozin
TN2020000045A1 (en) 2017-03-20 2021-10-04 Forma Therapeutics Inc Pyrrolopyrrole compositions as pyruvate kinase (pkr)
CN109796455B (zh) * 2017-11-17 2021-02-26 四川海思科制药有限公司 一种氨基吡喃衍生物的盐、其晶型及其制备方法和用途
CN111683659B (zh) * 2018-02-06 2023-08-29 四川海思科制药有限公司 一种氨基吡喃衍生物的组合物
CN113226356B (zh) 2018-09-19 2025-03-04 诺沃挪第克健康护理股份公司 活化丙酮酸激酶r
MA53668B1 (fr) 2018-09-19 2024-06-28 Novo Nordisk Health Care Ag Traitement de la drépanocytose avec un composé activant la pyruvate kinase r
EP4006017B1 (en) * 2019-07-26 2024-10-23 CGenetech (Suzhou, China) Co., Ltd. Sglt2/dpp4 inhibitor and application thereof
CN110568100B (zh) * 2019-09-12 2022-05-31 江西金水宝制药有限公司 一种米格列奈钙r-异构体的检测方法
CA3151612A1 (en) 2019-09-19 2021-03-25 George P. Luke Pyruvate kinase r (pkr) activating compositions
CN111793071B (zh) * 2020-07-06 2021-06-04 四川凯科医药科技有限公司 奥格列汀的合成工艺
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US5232929A (en) 1990-11-28 1993-08-03 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
IL111785A0 (en) 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
DE19616486C5 (de) 1996-04-25 2016-06-30 Royalty Pharma Collection Trust Verfahren zur Senkung des Blutglukosespiegels in Säugern
AR008789A1 (es) 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
JP2001515482A (ja) 1997-03-07 2001-09-18 メタバシス・セラピューティクス・インコーポレイテッド フルクトース−１，６−ビスホスファターゼの新規なベンズイミダゾールインヒビター
US6284748B1 (en) 1997-03-07 2001-09-04 Metabasis Therapeutics, Inc. Purine inhibitors of fructose 1,6-bisphosphatase
US6054587A (en) 1997-03-07 2000-04-25 Metabasis Therapeutics, Inc. Indole and azaindole inhibitors of fructose-1,6-bisphosphatase
US6613942B1 (en) 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
WO1999001423A1 (en) 1997-07-01 1999-01-14 Novo Nordisk A/S Glucagon antagonists/inverse agonists
PA8469501A1 (es) * 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
WO1999056753A1 (en) 1998-05-04 1999-11-11 Point Therapeutics, Inc. Hematopoietic stimulation
ATE246197T1 (de) 1998-09-09 2003-08-15 Metabasis Therapeutics Inc Neue heteroaromatische fructose 1,6- bisphosphatase inhibitoren
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
GB9906715D0 (en) 1999-03-23 1999-05-19 Ferring Bv Compositions for promoting growth
DE60023492T2 (de) 1999-05-17 2006-07-20 Novo Nordisk A/S Glucagon antagonisten/inverse agonisten
CA2415742A1 (en) 2000-07-25 2002-01-31 Merck & Co., Inc. N-substituted indoles useful in the treatment of diabetes
EP1328271B1 (en) 2000-10-27 2008-06-25 Probiodrug AG Treatment of neurological and neuropsychological disorders
CA2434491A1 (en) 2001-01-30 2002-08-08 Merck & Co., Inc. Acyl sulfamides for treatment of obesity, diabetes and lipid disorders
ES2291477T3 (es) 2001-06-27 2008-03-01 Smithkline Beecham Corporation Fluoropirrolidinas como inhibidores de dipeptidil peptidasa.
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
AR040241A1 (es) 2002-06-10 2005-03-23 Merck & Co Inc Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia
US7393960B2 (en) 2002-08-29 2008-07-01 Merck & Co., Inc. Indoles having anti-diabetic activity
US7186746B2 (en) 2002-08-29 2007-03-06 Merck & Co., Inc. Indoles having anti-diabetic activity
AU2003274652A1 (en) 2002-10-23 2004-05-13 Obetherapy Biotechnology Compounds, compositions and methods for modulating fat metabolism
US7192922B2 (en) 2002-11-19 2007-03-20 Allegheny-Singer Research Institute Method of treating left ventricular dysfunction
JO2397B1 (en) 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
CA2512879A1 (en) 2003-01-17 2004-08-12 Soumya P. Sahoo N-cyclohexylaminocarbonyl benzenesulfonamide derivatives
US7691603B2 (en) 2003-04-09 2010-04-06 Novo Nordisk A/S Intracellular formation of peptide conjugates
US7145012B2 (en) * 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US20040214856A1 (en) * 2003-04-23 2004-10-28 Pfizer Inc Cannabinoid receptor ligands and uses thereof
WO2005030751A2 (en) * 2003-09-08 2005-04-07 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
JP2007515434A (ja) 2003-12-23 2007-06-14 プロジェン インダストリーズ リミテッド グリコサミノグリカン（ｇａｇ）模倣物
AU2005265148B2 (en) 2004-06-21 2011-01-20 Merck Sharp & Dohme Corp. Aminocyclohexanes as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
WO2006020372A2 (en) 2004-07-23 2006-02-23 Neose Technologies, Inc. Enzymatic modification of glycopeptides
US7718667B2 (en) * 2004-09-28 2010-05-18 Merck Sharp & Dohme Corp. Fused aminopiperidines as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
EP1796669B1 (en) * 2004-10-01 2010-09-22 Merck Sharp & Dohme Corp. Aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
CN101035522B (zh) 2004-10-25 2011-12-07 诺瓦提斯公司 Dpp-ⅳ抑制剂、ppar抗糖尿病剂和二甲双胍的组合
ATE527259T1 (de) 2004-11-29 2011-10-15 Merck Sharp & Dohme Kondensierte aminopiperidine als dipeptidylpeptidase-iv-inhibitoren zur behandlung oder prävention von diabetes
KR100904829B1 (ko) 2004-12-20 2009-06-25 에프. 호프만-라 로슈 아게 4-아미노피페리딘 유도체
US7411093B2 (en) 2004-12-20 2008-08-12 Hoffman-La Roche Inc. Aminocycloalkanes as DPP-IV inhibitors
EP1702916A1 (en) 2005-03-18 2006-09-20 Santhera Pharmaceuticals (Schweiz) GmbH DPP-IV inhibitors
TWI357902B (en) * 2005-04-01 2012-02-11 Lg Life Science Ltd Dipeptidyl peptidase-iv inhibiting compounds, meth
ATE540950T1 (de) 2005-05-25 2012-01-15 Merck Sharp & Dohme Aminocyclohexane als dipeptidylpeptidase-iv- hemmer zur behandlung bzw. prävention von diabetes
PT1891105E (pt) 2005-06-13 2012-06-27 Imp Innovations Ltd Análogos de oxintomodulina e seus efeitos sobre o comportamento da alimentação
CA2619111C (en) 2005-08-26 2013-04-09 Merck & Co., Inc. Fused aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
AU2006326564B2 (en) 2005-12-14 2011-06-23 Merck Sharp & Dohme Corp. Fused aminopiperidines as dipeptidyl peptidase-4 inhibitors for the treatment or prevention of diabetes
CA2636757A1 (en) * 2006-01-25 2007-08-02 Tesfaye Biftu Aminocyclohexanes as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
CA2640924C (en) 2006-02-15 2013-10-08 Merck & Co., Inc. Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
EP2471811B1 (en) 2006-02-22 2015-09-16 Merck Sharp & Dohme Corp. Oxyntomodulin derivatives
RU2008141280A (ru) 2006-03-20 2010-04-27 Мерк энд Ко., Инк. (US) Агонисты рецептора нейромедина u и их применение
TW200806669A (en) * 2006-03-28 2008-02-01 Merck & Co Inc Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
JP5167250B2 (ja) 2006-05-16 2013-03-21 メルク・シャープ・エンド・ドーム・コーポレイション 糖尿病の治療又は予防のためのジペプチジルペプチダーゼｉｖ阻害剤としてのアミノテトラヒドロピラン
MX2009000748A (es) 2006-07-18 2009-03-31 Centocor Inc Mimeticuerpos de peptido-1 similar a glucagon de humano, composiciones, metodos y usos.
CA2668662A1 (en) * 2006-11-14 2008-05-22 Merck & Co., Inc. Tricyclic heteroaromatic compounds as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
JP6017754B2 (ja) 2007-02-15 2016-11-02 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ グルカゴン／ｇｌｐ−１受容体コアゴニスト
EP2170883A1 (en) 2007-06-28 2010-04-07 Merck Frosst Canada Ltd. Substituted fused pyrimidines as antagonists of gpr105 activity
CA2693214A1 (en) 2007-07-19 2009-01-22 Merck Sharp & Dohme Corp. Beta carboline derivatives as antidiabetic compounds
WO2009014676A1 (en) * 2007-07-23 2009-01-29 Merck & Co., Inc. Novel crystalline form of a dihydrochloride salt of a dipeptidyl peptidase-iv inhibitor
JP5313246B2 (ja) 2007-08-21 2013-10-09 メルク・シャープ・アンド・ドーム・コーポレーション 糖尿病の治療又は予防のためのジペプチジルペプチダーゼ−ｉｖ阻害剤としてのヘテロシクリル化合物
US20110301079A1 (en) 2007-09-21 2011-12-08 Instituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Neuromedin u receptor agonists and uses thereof
US7902376B2 (en) * 2008-01-23 2011-03-08 Merck Sharp & Dohme Corp. Process for preparing chiral dipeptidyl peptidase-IV inhibitor intermediates
WO2010047956A1 (en) 2008-10-08 2010-04-29 Bristol-Myers Squibb Company Azolopyrrolone melanin concentrating hormone receptor-1 antagonists
JO2870B1 (en) * 2008-11-13 2015-03-15 ميرك شارب اند دوهم كورب Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes

Also Published As

Publication number Publication date
MY150787A (en) 2014-02-28
HRP20130924T1 (hr) 2013-11-08
IL212485A0 (en) 2011-06-30
DOP2011000128A (es) 2011-06-30
AU2009314191A1 (en) 2010-05-20
PL2358717T3 (pl) 2014-01-31
TN2011000201A1 (en) 2012-12-17
JP2012508746A (ja) 2012-04-12
WO2010056708A1 (en) 2010-05-20
CR20110257A (es) 2011-07-01
EP2358717B1 (en) 2013-08-21
KR101454093B1 (ko) 2014-10-27
CA2742783C (en) 2013-01-08
US20150126443A1 (en) 2015-05-07
US20140287993A1 (en) 2014-09-25
TWI398443B (zh) 2013-06-11
CN102272136B (zh) 2015-01-14
US8143289B2 (en) 2012-03-27
PT2358717E (pt) 2013-11-26
EA018613B1 (ru) 2013-09-30
JP5537507B2 (ja) 2014-07-02
US20150344487A1 (en) 2015-12-03
JP2011251973A (ja) 2011-12-15
JP4854825B1 (ja) 2012-01-18
HK1154849A1 (en) 2012-05-04
EP2676960A1 (en) 2013-12-25
NZ592826A (en) 2012-06-29
BRPI0921375B1 (pt) 2020-11-03
PA8848201A1 (es) 2010-06-28
UA101414C2 (uk) 2013-03-25
GEP20135724B (en) 2013-01-10
CA2742783A1 (en) 2010-05-20
RS52946B (en) 2014-02-28
AU2009314191B2 (en) 2012-02-16
KR20120107133A (ko) 2012-09-28
MX2011005044A (es) 2011-06-17
US20130157940A1 (en) 2013-06-20
CN102272136A (zh) 2011-12-07
US20160137622A1 (en) 2016-05-19
ES2432191T3 (es) 2013-12-02
CY1114617T1 (el) 2016-10-05
IL225198A (en) 2016-02-29
CL2011001082A1 (es) 2012-02-24
US20140051740A1 (en) 2014-02-20
BRPI0921375A2 (pt) 2015-12-29
SI2358717T1 (sl) 2014-02-28
BRPI0921375B8 (pt) 2021-05-25
KR101260162B1 (ko) 2013-05-09
US8772328B2 (en) 2014-07-08
EA201170670A1 (ru) 2011-12-30
EP2676961B1 (en) 2017-04-19
IL212485A (en) 2013-08-29
TW201024299A (en) 2010-07-01
EP2676960B1 (en) 2017-04-19
JO2870B1 (en) 2015-03-15
US20120149637A1 (en) 2012-06-14
US20100120863A1 (en) 2010-05-13
PE20120027A1 (es) 2012-02-05
MA32887B1 (fr) 2011-12-01
US9278976B2 (en) 2016-03-08
US8415297B2 (en) 2013-04-09
US8592371B2 (en) 2013-11-26
US9138426B2 (en) 2015-09-22
HN2011001256A (es) 2013-10-14
EP2676961A1 (en) 2013-12-25
US9403790B2 (en) 2016-08-02
NI201100081A (es) 2011-11-03
ECSP11011044A (es) 2011-06-30
KR20110074581A (ko) 2011-06-30
US8951965B2 (en) 2015-02-10
SV2011003903A (es) 2011-10-13
AR074306A1 (es) 2011-01-05
EP2676959A1 (en) 2013-12-25
EP2358717A1 (en) 2011-08-24
CO6382129A2 (es) 2012-02-15

Similar Documents

Publication Publication Date Title
DK2358717T3 (da) Aminotetrahydropyraner som dipeptidylpeptidase-iv-inhibitorer tilbehandling eller forebyggelse af diabetes
IN2012DN00721A (da)
MX2008012490A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes.
WO2007097931A3 (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2007136603A3 (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2007087231A3 (en) Aminocyclohexanes as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2007070434A3 (en) Fused aminopiperidines as dipeptidyl peptidase-4 inhibitors for the treatment or prevention of diabetes
EP2571876A4 (en) 7-CHAIN SUBSTITUTED HETEROCYCLIC COMPOUNDS AS INHIBITORS OF DIPEPTIDYL-PEPTIDASE IV FOR THE TREATMENT OF DIABETES
WO2006058064A3 (en) Fused aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
EP1841770A4 (en) BICYCLIC PYRIMIDINES AS DIPEPTIDYLPEPTIDASE IV INHIBITORS FOR THE TREATMENT OF BZW. PREVENTION OF DIABETES
EP1796669A4 (en) AMINOPIPERIDINES AS DIPEPTIDYLPEPTIDASE IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
ATE540950T1 (de) Aminocyclohexane als dipeptidylpeptidase-iv- hemmer zur behandlung bzw. prävention von diabetes
EA201070635A1 (ru) Соединения, ингибирующие дипептидилпептидазу-iv,способы их получения и фармацевтические композиции, содержащие их в качестве активного агента
EA200970519A1 (ru) Полиморфы сукцината 2-[6-(3-аминопиперидин-1-ил)-3-метил-2,4-диоксо-3,4-дигидро-2h-пиримидин-1-илметил]-4-фторбензонитрил и способы их применения
EA201071320A1 (ru) Активаторы глюкокиназы
ATE549926T1 (de) Kondensierte aminopiperidine als dipeptidylpeptidase-iv-inhibitoren zur behandlung oder prävention von diabetes
BRPI0911035B8 (pt) ativadores de pirrolidinona glicoquinase
EA201100311A1 (ru) Амидные производные гетероарилов и их применение в качестве активаторов глюкокиназы
NO20070487L (no) 3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer.
EA201071367A1 (ru) Соли соединений ингибиторов вич
WO2012118945A3 (en) Fused bicyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors
WO2013006526A3 (en) Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors